Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb82
• Eyes On Eyecare62
• Alcon, Inc.53
• American Optometric Association44
• Harrow35
• Glaukos33
• Topcon Healthcare27
• Regeneron25
• Coopervision23
• Aldeyra Therapeutics22

Tags

• DME2
• FDA2
• Clinical Trials2
• Retina2

• Organizations: Surrozen✕

Clear all

Pipeline

FDA clears Surrozen's IND for DME therapy

First patient dosing in the DUET trial planned for later this year; study will be the first to evaluate humans treated with the bifunctional antibody.

Pipeline

Surrozen submits IND to FDA for DME therapeutic

Phase 1b/2a study to evaluate a bifunctional Wnt agonist and VEGF antagonist antibody that targets vascular leakage and promote retinal vascular integrity